Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Ex-Legend CEO Takes Helm at Biotech Startup Scouring the Globe for Drugs

Summary by biopharmadive.com
Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

3 Articles

biopharmadive.combiopharmadive.com
Center

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Read Full Article
endpoints.newsendpoints.news

Ying Huang's post-Legend life takes shape at K2, with $250M goal to license Asia assets

Ying Huang has spent the past seven years building up one of the leading cancer cell therapy players. Now, just weeks after announcing his departure as Legend Biotech's CEO, Huang is stepping ...

Read Full Article
Business TimesBusiness Times

Singapore-based biotech K2 Therapeutics secures US$50 million seed round; appoints Huang Ying as CEO

Huang’s immediate focus is to raise funding to support development of firm’s four assets Read more at The Business Times.

·Singapore, Singapore
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Business Times broke the news in Singapore, Singapore on Tuesday, August 11, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Pharma icon

Pharma

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal